Overview

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study a new treatment for HER2-positive breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
GlaxoSmithKline
Treatments:
Albumin-Bound Paclitaxel
Lapatinib
Paclitaxel
Trastuzumab